Estradiol levels over a 24-hour period following a single 0.25, 0.5, or 1 mg dose of sublingual estradiol or a single 0.5 or 1 mg dose of oral estradiol in postmenopausal women.[1] Source: Price et al. (1997).[1]
Hormone levels after a single 0.5 mg dose of sublingual estradiol in postmenopausal women.[2] Source: Burnier et al. (1981).[2]
Hormone levels after a single 2 mg dose of sublingual estradiol in premenopausal women.[3] Source: Casper & Yen (1981).[3]
Hormone levels after a single 0.5 mg dose of sublingual estradiol in postmenopausal women.[4] Source: Fiet et al. (1982).[4]
Estradiol levels with 2 to 12 mg/day sublingual estradiol in transgender women.[5] Error bars are
SEM. Time of blood collection and time and frequency of administration were not specified.[5] Source: Jain et al. (2019).[5]
Hormone levels with 2 mg oral micronized estradiol valerate tablets (Progynova, Schering) taken 3 or 4 times per day (6–8 mg/day total) sublingually (SL) in premenopausal women.[6][7] Time of blood collection after medication administration was not specified.[6][7] Sources: Serhal et al. (1989, 1990).[6][7]
Trough estradiol levels and
MADRSTooltip Montgomery–Åsberg Depression Rating Scale scores with 1 mg sublingual micronized estradiol 3 to 8 times per day (3 to 8 mg/day total; mean 4.8 mg/day total) in women with
postpartum depression.[8] Blood was drawn specifically in the mornings before the first dose of sublingual estradiol for the day.[8] Source: Akohas et al. (2001).[8]
^
abFiet J, Hermano M, Witte J, Villette JM, Haimart M, Gourmel B, Tabuteau F, Rouffy J, Dreux C (September 1982). "Post-menopausal concentrations of plasma oestradiol, oestrone, FSH and LH and of total urinary oestradiol and oestrone after a single sublingual dose of oestradiol-17 beta". Acta Endocrinol. 101 (1): 93–7.
doi:
10.1530/acta.0.1010093.
PMID6812348.
^
abcJain J, Kwan D, Forcier M (April 2019). "Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results from a Retrospective Study". The Journal of Clinical Endocrinology & Metabolism. 104 (11): 5148–5156.
doi:
10.1210/jc.2018-02253.
ISSN0021-972X.
PMID31127826.
S2CID149715362.
Estradiol levels over a 24-hour period following a single 0.25, 0.5, or 1 mg dose of sublingual estradiol or a single 0.5 or 1 mg dose of oral estradiol in postmenopausal women.[1] Source: Price et al. (1997).[1]
Hormone levels after a single 0.5 mg dose of sublingual estradiol in postmenopausal women.[2] Source: Burnier et al. (1981).[2]
Hormone levels after a single 2 mg dose of sublingual estradiol in premenopausal women.[3] Source: Casper & Yen (1981).[3]
Hormone levels after a single 0.5 mg dose of sublingual estradiol in postmenopausal women.[4] Source: Fiet et al. (1982).[4]
Estradiol levels with 2 to 12 mg/day sublingual estradiol in transgender women.[5] Error bars are
SEM. Time of blood collection and time and frequency of administration were not specified.[5] Source: Jain et al. (2019).[5]
Hormone levels with 2 mg oral micronized estradiol valerate tablets (Progynova, Schering) taken 3 or 4 times per day (6–8 mg/day total) sublingually (SL) in premenopausal women.[6][7] Time of blood collection after medication administration was not specified.[6][7] Sources: Serhal et al. (1989, 1990).[6][7]
Trough estradiol levels and
MADRSTooltip Montgomery–Åsberg Depression Rating Scale scores with 1 mg sublingual micronized estradiol 3 to 8 times per day (3 to 8 mg/day total; mean 4.8 mg/day total) in women with
postpartum depression.[8] Blood was drawn specifically in the mornings before the first dose of sublingual estradiol for the day.[8] Source: Akohas et al. (2001).[8]
^
abFiet J, Hermano M, Witte J, Villette JM, Haimart M, Gourmel B, Tabuteau F, Rouffy J, Dreux C (September 1982). "Post-menopausal concentrations of plasma oestradiol, oestrone, FSH and LH and of total urinary oestradiol and oestrone after a single sublingual dose of oestradiol-17 beta". Acta Endocrinol. 101 (1): 93–7.
doi:
10.1530/acta.0.1010093.
PMID6812348.
^
abcJain J, Kwan D, Forcier M (April 2019). "Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results from a Retrospective Study". The Journal of Clinical Endocrinology & Metabolism. 104 (11): 5148–5156.
doi:
10.1210/jc.2018-02253.
ISSN0021-972X.
PMID31127826.
S2CID149715362.